UK’s drug-cost watchdog recommends Alnylam’s heart disease drug
(Reuters) -The UK’s drug cost-effectiveness watchdog has recommended Alnylam Pharmaceuticals’ heart disease drug, ensuring access for patients through the government health system in England and Wales, the company said on Friday. The country’s drug regulator had approved the injectable drug, Amvuttra, in July to treat ATTR-CM, a condition where faulty transthyretin proteins accumulate in the …
UK’s drug-cost watchdog recommends Alnylam’s heart disease drug Read More »










